T1	Participants 56 97	chronic central serous chorioretinopathy:
T2	Participants 422 620	Thirty-four eyes of 32 patients with chronic CSC with >6 months' duration of symptoms or recurrent CSC were randomly placed into the low-fluence PDT group (n = 18) or the ranibizumab group (n = 16).
T3	Participants 1341 1348	16 eyes
T4	Participants 1456 1462	2 eyes
